Showing 3611-3620 of 7372 results for "".
- BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://practicaldermatology.com/news/btl-to-showcase-groundbreaking-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2457817/BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) tak
- Skin May Lose Long-Standing Title of Body's Largest Organ to the “Interstitium”https://practicaldermatology.com/news/skin-may-lose-long-standing-title-of-bodys-largest-organ-to-the-interstitium/2457823/The skin has always been considered the largest organ in the body, but it may have some competition -- the newly defined interstitium. The Feinstein Institute for Medical Research researcher Petros Constantinos Benias, MD, and collaborator
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- Hair Loss Drug May Boost Heart Healthhttps://practicaldermatology.com/news/hair-loss-drug-may-boost-heart-health/2457833/Oral minoxidil may improve blood flow to the brain, lower blood pressure and increase elasticity in the blood vessels, according to a new study in mice. The article is published in the American Journal of Physiology&mdash
- Botanical Dermatology Brand Kamedis Forms U.S. Medical Advisory Boardhttps://practicaldermatology.com/news/botanical-dermatology-brand-kamedis-forms-us-medical-advisory-board/2457834/Israeli-based Kamedis announced the formation of a U.S. medical advisory board. The members include: Zoe Draelos, MD, FAAD, a clinical and research dermatologist with a private solo practice in High Point, NC, who is also a Consulting Professo
- New Recommendations Aim to Minimize Biotin Interference in Clinical Immunoassayshttps://practicaldermatology.com/news/new-recommendations-aim-to-minimize-biotin-interference-in-clinical-immunoassays/2457842/As the popularity of biotin has grown, so has the incidence of this vitamin interfering with critical medical tests, and now a review in The Journal of Applied Laboratory Medicine provides expert recommendat
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- CareCredit Moves Into Day and Med Spa Marketshttps://practicaldermatology.com/news/carecredit-moves-into-day-and-med-spa-markets/2457847/CareCredit is expanding into the day and medical spa markets. As part of this new program, CareCredit partnered with both the American Med Spa Association and the Spa Industry Association to bring the benefits of CareCredit to their practices. Providers can now offer clients acces
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil